<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">33452054</PMID><DateCompleted><Year>2022</Year><Month>01</Month><Day>03</Day></DateCompleted><DateRevised><Year>2022</Year><Month>01</Month><Day>03</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1468-330X</ISSN><JournalIssue CitedMedium="Internet"><Volume>92</Volume><Issue>5</Issue><PubDate><Year>2021</Year><Month>May</Month></PubDate></JournalIssue><Title>Journal of neurology, neurosurgery, and psychiatry</Title><ISOAbbreviation>J Neurol Neurosurg Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Unravelling the clinical spectrum and the role of repeat length in <i>C9ORF72</i> repeat expansions.</ArticleTitle><Pagination><StartPage>502</StartPage><EndPage>509</EndPage><MedlinePgn>502-509</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1136/jnnp-2020-325377</ELocationID><Abstract><AbstractText>Since the discovery of the <i>C9orf72</i> repeat expansion as the most common genetic cause of frontotemporal dementia (FTD) and amyotrophic lateral sclerosis, it has increasingly been associated with a wider spectrum of phenotypes, including other types of dementia, movement disorders, psychiatric symptoms and slowly progressive FTD. Prompt recognition of patients with <i>C9orf72</i>-associated diseases is essential in light of upcoming clinical trials. The striking clinical heterogeneity associated with <i>C9orf72</i> repeat expansions remains largely unexplained. In contrast to other repeat expansion disorders, evidence for an effect of repeat length on phenotype is inconclusive. Patients with <i>C9orf72</i>-associated diseases typically have very long repeat expansions, containing hundreds to thousands of GGGGCC-repeats, but smaller expansions might also have clinical significance. The exact threshold at which repeat expansions lead to neurodegeneration is unknown, and discordant cut-offs between laboratories pose a challenge for genetic counselling. Accurate and large-scale measurement of repeat expansions has been severely hindered by technical difficulties in sizing long expansions and by variable repeat lengths across and within tissues. Novel long-read sequencing approaches have produced promising results and open up avenues to further investigate this enthralling repeat expansion, elucidating whether its length, purity, and methylation pattern might modulate clinical features of <i>C9orf72</i>-related diseases.</AbstractText><CopyrightInformation>&#xa9; Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>van der Ende</LastName><ForeName>Emma L</ForeName><Initials>EL</Initials><Identifier Source="ORCID">0000-0003-2570-8796</Identifier><AffiliationInfo><Affiliation>Department of Neurology and Alzheimer Center, Erasmus University Medical Center, Rotterdam, Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Jackson</LastName><ForeName>Jazmyne L</ForeName><Initials>JL</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic, Jacksonville, Florida, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>White</LastName><ForeName>Adrianna</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic, Jacksonville, Florida, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biology, University of North Florida, Jacksonville, Florida, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Seelaar</LastName><ForeName>Harro</ForeName><Initials>H</Initials><Identifier Source="ORCID">0000-0003-1989-7527</Identifier><AffiliationInfo><Affiliation>Department of Neurology and Alzheimer Center, Erasmus University Medical Center, Rotterdam, Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>van Blitterswijk</LastName><ForeName>Marka</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-3054-7053</Identifier><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic, Jacksonville, Florida, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biology, University of North Florida, Jacksonville, Florida, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Van Swieten</LastName><ForeName>John C</ForeName><Initials>JC</Initials><Identifier Source="ORCID">0000-0001-6278-6844</Identifier><AffiliationInfo><Affiliation>Department of Neurology and Alzheimer Center, Erasmus University Medical Center, Rotterdam, Netherlands j.c.vanswieten@erasmusmc.nl.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R21 NS110994</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R21 NS099631</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>01</Month><Day>15</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>J Neurol Neurosurg Psychiatry</MedlineTA><NlmUniqueID>2985191R</NlmUniqueID><ISSNLinking>0022-3050</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000073885">C9orf72 Protein</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000073885" MajorTopicYN="N">C9orf72 Protein</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019175" MajorTopicYN="N">DNA Methylation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D042622" MajorTopicYN="Y">DNA Repeat Expansion</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057180" MajorTopicYN="N">Frontotemporal Dementia</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010641" MajorTopicYN="N">Phenotype</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">ALS</Keyword><Keyword MajorTopicYN="N">C9ORF72</Keyword><Keyword MajorTopicYN="N">frontotemporal dementia</Keyword></KeywordList><CoiStatement>Competing interests: None declared.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>10</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2020</Year><Month>12</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>12</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>1</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>1</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>1</Month><Day>16</Day><Hour>5</Hour><Minute>32</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33452054</ArticleId><ArticleId IdType="pmc">PMC8053328</ArticleId><ArticleId IdType="doi">10.1136/jnnp-2020-325377</ArticleId><ArticleId IdType="pii">jnnp-2020-325377</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>DeJesus-Hernandez M, Mackenzie IR, Boeve BF, et al. . Expanded GGGGCC hexanucleotide repeat in noncoding region of C9orf72 causes chromosome 9p-linked FTD and ALS. Neuron 2011;72:245&#x2013;56. 10.1016/j.neuron.2011.09.011</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2011.09.011</ArticleId><ArticleId IdType="pmc">PMC3202986</ArticleId><ArticleId IdType="pubmed">21944778</ArticleId></ArticleIdList></Reference><Reference><Citation>Renton AE, Majounie E, Waite A, et al. . A hexanucleotide repeat expansion in C9orf72 is the cause of chromosome 9p21-linked ALS-FTD. Neuron 2011;72:257&#x2013;68. 10.1016/j.neuron.2011.09.010</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2011.09.010</ArticleId><ArticleId IdType="pmc">PMC3200438</ArticleId><ArticleId IdType="pubmed">21944779</ArticleId></ArticleIdList></Reference><Reference><Citation>Beck J, Poulter M, Hensman D, et al. . Large C9orf72 hexanucleotide repeat expansions are seen in multiple neurodegenerative syndromes and are more frequent than expected in the UK population. Am J Hum Genet 2013;92:345&#x2013;53. 10.1016/j.ajhg.2013.01.011</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ajhg.2013.01.011</ArticleId><ArticleId IdType="pmc">PMC3591848</ArticleId><ArticleId IdType="pubmed">23434116</ArticleId></ArticleIdList></Reference><Reference><Citation>Majounie E, Renton AE, Mok K, et al. . Frequency of the C9orf72 hexanucleotide repeat expansion in patients with amyotrophic lateral sclerosis and frontotemporal dementia: a cross-sectional study. Lancet Neurol 2012;11:323&#x2013;30. 10.1016/S1474-4422(12)70043-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(12)70043-1</ArticleId><ArticleId IdType="pmc">PMC3322422</ArticleId><ArticleId IdType="pubmed">22406228</ArticleId></ArticleIdList></Reference><Reference><Citation>Paulson H. Repeat expansion diseases. Handb Clin Neurol 2018;147:105&#x2013;23. 10.1016/B978-0-444-63233-3.00009-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/B978-0-444-63233-3.00009-9</ArticleId><ArticleId IdType="pmc">PMC6485936</ArticleId><ArticleId IdType="pubmed">29325606</ArticleId></ArticleIdList></Reference><Reference><Citation>Akimoto C, Volk AE, van Blitterswijk M, et al. . A blinded International study on the reliability of genetic testing for GGGGCC-repeat expansions in C9orf72 reveals marked differences in results among 14 laboratories. J Med Genet 2014;51:419&#x2013;24. 10.1136/jmedgenet-2014-102360</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jmedgenet-2014-102360</ArticleId><ArticleId IdType="pmc">PMC4033024</ArticleId><ArticleId IdType="pubmed">24706941</ArticleId></ArticleIdList></Reference><Reference><Citation>H&#xfc;bers A, Marroquin N, Schmoll B, et al. . Polymerase chain reaction and southern blot-based analysis of the C9orf72 hexanucleotide repeat in different motor neuron diseases. Neurobiol Aging 2014;35:1214.e1&#x2013;1214.e6. 10.1016/j.neurobiolaging.2013.11.034</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2013.11.034</ArticleId><ArticleId IdType="pubmed">24378086</ArticleId></ArticleIdList></Reference><Reference><Citation>van Blitterswijk M, DeJesus-Hernandez M, Niemantsverdriet E, et al. . Association between repeat sizes and clinical and pathological characteristics in carriers of C9orf72 repeat expansions (Xpansize-72): a cross-sectional cohort study. Lancet Neurol 2013;12:978&#x2013;88. 10.1016/S1474-4422(13)70210-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(13)70210-2</ArticleId><ArticleId IdType="pmc">PMC3879782</ArticleId><ArticleId IdType="pubmed">24011653</ArticleId></ArticleIdList></Reference><Reference><Citation>van der Zee J, Gijselinck I, Dillen L, et al. . A pan-European study of the C9orf72 repeat associated with FTLD: geographic prevalence, genomic instability, and intermediate repeats. Hum Mutat 2013;34:363&#x2013;73. 10.1002/humu.22244</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/humu.22244</ArticleId><ArticleId IdType="pmc">PMC3638346</ArticleId><ArticleId IdType="pubmed">23111906</ArticleId></ArticleIdList></Reference><Reference><Citation>Balendra R, Isaacs AM. C9orf72-mediated ALS and FTD: multiple pathways to disease. Nat Rev Neurol 2018;14:544&#x2013;58. 10.1038/s41582-018-0047-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41582-018-0047-2</ArticleId><ArticleId IdType="pmc">PMC6417666</ArticleId><ArticleId IdType="pubmed">30120348</ArticleId></ArticleIdList></Reference><Reference><Citation>Tang X, Toro A, T G S, et al. . Divergence, convergence, and therapeutic implications: a cell biology perspective of C9ORF72-ALS/FTD. Mol Neurodegener 2020;15:34. 10.1186/s13024-020-00383-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13024-020-00383-7</ArticleId><ArticleId IdType="pmc">PMC7282082</ArticleId><ArticleId IdType="pubmed">32513219</ArticleId></ArticleIdList></Reference><Reference><Citation>Marogianni C, Rikos D, Provatas A, et al. . The role of C9orf72 in neurodegenerative disorders: a systematic review, an updated meta-analysis, and the creation of an online database. Neurobiol Aging 2019;84:238.e25&#x2013;238.e34. 10.1016/j.neurobiolaging.2019.04.012</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2019.04.012</ArticleId><ArticleId IdType="pubmed">31126629</ArticleId></ArticleIdList></Reference><Reference><Citation>Cammack AJ, Atassi N, Hyman T, et al. . Prospective natural history study of C9orf72 ALS clinical characteristics and biomarkers. Neurology 2019;93:10.1212/WNL.0000000000008359&#x2013;17. 10.1212/WNL.0000000000008359</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000008359</ArticleId><ArticleId IdType="pmc">PMC6946465</ArticleId><ArticleId IdType="pubmed">31578300</ArticleId></ArticleIdList></Reference><Reference><Citation>Glasmacher SA, Wong C, Pearson IE, et al. . Survival and prognostic factors in C9orf72 repeat expansion carriers: a systematic review and meta-analysis. JAMA Neurol 2020;77:367&#x2013;76. 10.1001/jamaneurol.2019.3924</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2019.3924</ArticleId><ArticleId IdType="pmc">PMC6865318</ArticleId><ArticleId IdType="pubmed">31738367</ArticleId></ArticleIdList></Reference><Reference><Citation>Snowden JS, Rollinson S, Thompson JC, et al. . Distinct clinical and pathological characteristics of frontotemporal dementia associated with C9orf72 mutations. Brain 2012;135:693&#x2013;708. 10.1093/brain/awr355</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awr355</ArticleId><ArticleId IdType="pmc">PMC3286329</ArticleId><ArticleId IdType="pubmed">22300873</ArticleId></ArticleIdList></Reference><Reference><Citation>Rascovsky K, Hodges JR, Knopman D, et al. . Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. Brain 2011;134:2456&#x2013;77. 10.1093/brain/awr179</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awr179</ArticleId><ArticleId IdType="pmc">PMC3170532</ArticleId><ArticleId IdType="pubmed">21810890</ArticleId></ArticleIdList></Reference><Reference><Citation>Devenney E, Hornberger M, Irish M, et al. . Frontotemporal dementia associated with the C9orf72 mutation: a unique clinical profile. JAMA Neurol 2014;71:331&#x2013;9. 10.1001/jamaneurol.2013.6002</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2013.6002</ArticleId><ArticleId IdType="pubmed">24445580</ArticleId></ArticleIdList></Reference><Reference><Citation>Cacace R, Van Cauwenberghe C, Bettens K, et al. . C9orf72 G4C2 repeat expansions in Alzheimer&#x2019;s disease and mild cognitive impairment. Neurobiol Aging 2013;34:1712.e1&#x2013;1712.e7. 10.1016/j.neurobiolaging.2012.12.019</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2012.12.019</ArticleId><ArticleId IdType="pubmed">23352322</ArticleId></ArticleIdList></Reference><Reference><Citation>Mahoney CJ, Beck J, Rohrer JD, et al. . Frontotemporal dementia with the C9orf72 hexanucleotide repeat expansion: clinical, neuroanatomical and neuropathological features. Brain 2012;135:736&#x2013;50. 10.1093/brain/awr361</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awr361</ArticleId><ArticleId IdType="pmc">PMC3286330</ArticleId><ArticleId IdType="pubmed">22366791</ArticleId></ArticleIdList></Reference><Reference><Citation>Khan BK, Yokoyama JS, Takada LT, et al. . Atypical, slowly progressive behavioural variant frontotemporal dementia associated with C9orf72 hexanucleotide expansion. J Neurol Neurosurg Psychiatry 2012;83:358&#x2013;64. 10.1136/jnnp-2011-301883</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2011-301883</ArticleId><ArticleId IdType="pmc">PMC3388906</ArticleId><ArticleId IdType="pubmed">22399793</ArticleId></ArticleIdList></Reference><Reference><Citation>Llamas-Velasco S, Garc&#xed;a-Redondo A, Herrero-San Mart&#xed;n A, et al. . Slowly progressive behavioral frontotemporal dementia with C9orf72 mutation. Case report and review of the literature. Neurocase 2018;24:68&#x2013;71. 10.1080/13554794.2018.1428353</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/13554794.2018.1428353</ArticleId><ArticleId IdType="pubmed">29355451</ArticleId></ArticleIdList></Reference><Reference><Citation>Harms M, Benitez BA, Cairns N, et al. . C9Orf72 hexanucleotide repeat expansions in clinical Alzheimer disease. JAMA Neurol 2013;70:736&#x2013;41. 10.1001/2013.jamaneurol.537</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/2013.jamaneurol.537</ArticleId><ArticleId IdType="pmc">PMC3681841</ArticleId><ArticleId IdType="pubmed">23588422</ArticleId></ArticleIdList></Reference><Reference><Citation>Bieniek KF, Murray ME, Rutherford NJ, et al. . Tau pathology in frontotemporal lobar degeneration with C9orf72 hexanucleotide repeat expansion. Acta Neuropathol 2013;125:289&#x2013;302. 10.1007/s00401-012-1048-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-012-1048-7</ArticleId><ArticleId IdType="pmc">PMC3551994</ArticleId><ArticleId IdType="pubmed">23053135</ArticleId></ArticleIdList></Reference><Reference><Citation>Majounie E, Abramzon Y, Renton AE, et al. . Repeat expansion in C9orf72 in Alzheimer's disease. N Engl J Med 2012;366:283&#x2013;4. 10.1056/NEJMc1113592</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMc1113592</ArticleId><ArticleId IdType="pmc">PMC3513272</ArticleId><ArticleId IdType="pubmed">22216764</ArticleId></ArticleIdList></Reference><Reference><Citation>Solje E, Aaltokallio H, Koivumaa-Honkanen H, et al. . The phenotype of the C9orf72 expansion carriers according to revised criteria for bvFTD. PLoS One 2015;10:e0131817. 10.1371/journal.pone.0131817</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0131817</ArticleId><ArticleId IdType="pmc">PMC4493025</ArticleId><ArticleId IdType="pubmed">26146826</ArticleId></ArticleIdList></Reference><Reference><Citation>Bieniek KF, van Blitterswijk M, Baker MC, et al. . Expanded C9orf72 hexanucleotide repeat in depressive pseudodementia. JAMA Neurol 2014;71:775&#x2013;81. 10.1001/jamaneurol.2013.6368</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2013.6368</ArticleId><ArticleId IdType="pmc">PMC4197801</ArticleId><ArticleId IdType="pubmed">24756204</ArticleId></ArticleIdList></Reference><Reference><Citation>Block NR, Sha SJ, Karydas AM, et al. . Frontotemporal dementia and psychiatric illness: emerging clinical and biological links in gene carriers. Am J Geriatr Psychiatry 2016;24:107&#x2013;16. 10.1016/j.jagp.2015.04.007</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jagp.2015.04.007</ArticleId><ArticleId IdType="pmc">PMC4686378</ArticleId><ArticleId IdType="pubmed">26324540</ArticleId></ArticleIdList></Reference><Reference><Citation>Fahey C, Byrne S, McLaughlin R, et al. . Analysis of the hexanucleotide repeat expansion and founder haplotype at C9orf72 in an Irish psychosis case-control sample. Neurobiol Aging 2014;35:1510.e1&#x2013;1510.e5. 10.1016/j.neurobiolaging.2013.12.003</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2013.12.003</ArticleId><ArticleId IdType="pubmed">24411481</ArticleId></ArticleIdList></Reference><Reference><Citation>Solje E, Miettunen J, Marttila R, et al. . The C9orf72 expansion sizes in patients with psychosis: a population-based study on the Northern Finland birth cohort 1966. Psychiatr Genet 2016;26:92&#x2013;4. 10.1097/YPG.0000000000000118</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/YPG.0000000000000118</ArticleId><ArticleId IdType="pubmed">26862832</ArticleId></ArticleIdList></Reference><Reference><Citation>Boeve BF, Boylan KB, Graff-Radford NR, et al. . Characterization of frontotemporal dementia and/or amyotrophic lateral sclerosis associated with the GGGGCC repeat expansion in C9orf72. Brain 2012;135:765&#x2013;83. 10.1093/brain/aws004</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/aws004</ArticleId><ArticleId IdType="pmc">PMC3286335</ArticleId><ArticleId IdType="pubmed">22366793</ArticleId></ArticleIdList></Reference><Reference><Citation>Carneiro F, Saracino D, Huin V, et al. . Isolated parkinsonism is an atypical presentation of GRN and C9orf72 gene mutations. Parkinsonism Relat Disord 2020;80:73&#x2013;81. 10.1016/j.parkreldis.2020.09.019</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.parkreldis.2020.09.019</ArticleId><ArticleId IdType="pubmed">32961397</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilke C, Pomper JK, Biskup S, et al. . Atypical parkinsonism in C9orf72 expansions: a case report and systematic review of 45 cases from the literature. J Neurol 2016;263:558&#x2013;74. 10.1007/s00415-016-8021-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00415-016-8021-7</ArticleId><ArticleId IdType="pubmed">26810719</ArticleId></ArticleIdList></Reference><Reference><Citation>Lesage S, Le Ber I, Condroyer C, et al. . C9Orf72 repeat expansions are a rare genetic cause of parkinsonism. Brain 2013;136:385&#x2013;91. 10.1093/brain/aws357</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/aws357</ArticleId><ArticleId IdType="pmc">PMC3984141</ArticleId><ArticleId IdType="pubmed">23413259</ArticleId></ArticleIdList></Reference><Reference><Citation>Cooper-Knock J, Frolov A, Highley JR, et al. . C9Orf72 expansions, parkinsonism, and Parkinson disease: a clinicopathologic study. Neurology 2013;81:808&#x2013;11. 10.1212/WNL.0b013e3182a2cc38</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0b013e3182a2cc38</ArticleId><ArticleId IdType="pmc">PMC3908460</ArticleId><ArticleId IdType="pubmed">23884045</ArticleId></ArticleIdList></Reference><Reference><Citation>Shivji S, Wong W, Fischer CE, et al. . Parkinsonism in C9orf72 expansion without co-existing Lewy body pathology; a case report and review of the literature. Neuropathol Appl Neurobiol 2020;46:786&#x2013;9. 10.1111/nan.12623</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/nan.12623</ArticleId><ArticleId IdType="pubmed">32339329</ArticleId></ArticleIdList></Reference><Reference><Citation>Theuns J, Verstraeten A, Sleegers K, et al. . Global investigation and meta-analysis of the C9orf72 (G4C2)n repeat in Parkinson disease. Neurology 2014;83:1906&#x2013;13. 10.1212/WNL.0000000000001012</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000001012</ArticleId><ArticleId IdType="pmc">PMC4248456</ArticleId><ArticleId IdType="pubmed">25326098</ArticleId></ArticleIdList></Reference><Reference><Citation>Nuytemans K, Inchausti V, Beecham GW, et al. . Absence of C9orf72 expanded or intermediate repeats in autopsy-confirmed Parkinson's disease. Mov Disord 2014;29:827&#x2013;30. 10.1002/mds.25838</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mds.25838</ArticleId><ArticleId IdType="pmc">PMC4022044</ArticleId><ArticleId IdType="pubmed">24573903</ArticleId></ArticleIdList></Reference><Reference><Citation>Hensman Moss DJ, Poulter M, Beck J, et al. . C9Orf72 expansions are the most common genetic cause of Huntington disease phenocopies. Neurology 2014;82:292&#x2013;9. 10.1212/WNL.0000000000000061</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000000061</ArticleId><ArticleId IdType="pmc">PMC3929197</ArticleId><ArticleId IdType="pubmed">24363131</ArticleId></ArticleIdList></Reference><Reference><Citation>Martins J, Dam&#xe1;sio J, Mendes A, et al. . Clinical spectrum of C9orf72 expansion in a cohort of Huntington's disease phenocopies. Neurol Sci 2018;39:741&#x2013;4. 10.1007/s10072-018-3268-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10072-018-3268-7</ArticleId><ArticleId IdType="pubmed">29441485</ArticleId></ArticleIdList></Reference><Reference><Citation>Roggenbuck J, Fong JC. Genetic testing for amyotrophic lateral sclerosis and frontotemporal dementia: impact on clinical management. Clin Lab Med 2020;40:271&#x2013;87. 10.1016/j.cll.2020.05.002</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cll.2020.05.002</ArticleId><ArticleId IdType="pubmed">32718499</ArticleId></ArticleIdList></Reference><Reference><Citation>Ducharme S, Dols A, Laforce R, et al. . Recommendations to distinguish behavioural variant frontotemporal dementia from psychiatric disorders. Brain 2020;143:1632&#x2013;50. 10.1093/brain/awaa018</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awaa018</ArticleId><ArticleId IdType="pmc">PMC7849953</ArticleId><ArticleId IdType="pubmed">32129844</ArticleId></ArticleIdList></Reference><Reference><Citation>Crook A, McEwen A, Fifita JA, et al. . The C9orf72 hexanucleotide repeat expansion presents a challenge for testing laboratories and genetic counseling. Amyotroph Lateral Scler Frontotemporal Degener 2019;20:310&#x2013;6. 10.1080/21678421.2019.1588904</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2019.1588904</ArticleId><ArticleId IdType="pubmed">30907153</ArticleId></ArticleIdList></Reference><Reference><Citation>Fratta P, Polke JM, Newcombe J, et al. . Screening a UK amyotrophic lateral sclerosis cohort provides evidence of multiple origins of the C9orf72 expansion. Neurobiol Aging 2015;36:546.e1&#x2013;546.e7. 10.1016/j.neurobiolaging.2014.07.037</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2014.07.037</ArticleId><ArticleId IdType="pmc">PMC4270445</ArticleId><ArticleId IdType="pubmed">25179228</ArticleId></ArticleIdList></Reference><Reference><Citation>Gijselinck I, Van Mossevelde S, van der Zee J, et al. . The C9orf72 repeat size correlates with onset age of disease, DNA methylation and transcriptional downregulation of the promoter. Mol Psychiatry 2016;21:1112&#x2013;24. 10.1038/mp.2015.159</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/mp.2015.159</ArticleId><ArticleId IdType="pmc">PMC4960451</ArticleId><ArticleId IdType="pubmed">26481318</ArticleId></ArticleIdList></Reference><Reference><Citation>McGoldrick P, Zhang M, van Blitterswijk M, et al. . Unaffected mosaic C9orf72 case: RNA foci, dipeptide proteins, but upregulated C9orf72 expression. Neurology 2018;90:e323&#x2013;31. 10.1212/WNL.0000000000004865</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000004865</ArticleId><ArticleId IdType="pmc">PMC5798652</ArticleId><ArticleId IdType="pubmed">29282338</ArticleId></ArticleIdList></Reference><Reference><Citation>Dols-Icardo O, Garc&#xed;a-Redondo A, Rojas-Garc&#xed;a R, et al. . Characterization of the repeat expansion size in C9orf72 in amyotrophic lateral sclerosis and frontotemporal dementia. Hum Mol Genet 2014;23:749&#x2013;54. 10.1093/hmg/ddt460</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddt460</ArticleId><ArticleId IdType="pubmed">24057670</ArticleId></ArticleIdList></Reference><Reference><Citation>Jackson JL, Finch NA, Baker MC, et al. . Elevated methylation levels, reduced expression levels, and frequent contractions in a clinical cohort of C9orf72 expansion carriers. Mol Neurodegener 2020;15:7. 10.1186/s13024-020-0359-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13024-020-0359-8</ArticleId><ArticleId IdType="pmc">PMC6993399</ArticleId><ArticleId IdType="pubmed">32000838</ArticleId></ArticleIdList></Reference><Reference><Citation>Nordin A, Akimoto C, Wuolikainen A, et al. . Extensive size variability of the GGGGCC expansion in C9orf72 in both neuronal and non-neuronal tissues in 18 patients with ALS or FTD. Hum Mol Genet 2015;24:3133&#x2013;42. 10.1093/hmg/ddv064</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddv064</ArticleId><ArticleId IdType="pubmed">25712133</ArticleId></ArticleIdList></Reference><Reference><Citation>Suh E, Lee EB, Neal D, et al. . Semi-Automated quantification of C9orf72 expansion size reveals inverse correlation between hexanucleotide repeat number and disease duration in frontotemporal degeneration. Acta Neuropathol 2015;130:363&#x2013;72. 10.1007/s00401-015-1445-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-015-1445-9</ArticleId><ArticleId IdType="pmc">PMC4545720</ArticleId><ArticleId IdType="pubmed">26022924</ArticleId></ArticleIdList></Reference><Reference><Citation>Ross JP, Leblond CS, Catoire H, et al. . Somatic expansion of the C9orf72 hexanucleotide repeat does not occur in ALS spinal cord tissues. Neurol Genet 2019;5:e317. 10.1212/NXG.0000000000000317</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/NXG.0000000000000317</ArticleId><ArticleId IdType="pmc">PMC6454309</ArticleId><ArticleId IdType="pubmed">31041398</ArticleId></ArticleIdList></Reference><Reference><Citation>Fournier C, Barbier M, Camuzat A, et al. . Relations between C9orf72 expansion size in blood, age at onset, age at collection and transmission across generations in patients and presymptomatic carriers. Neurobiol Aging 2019;74:234.e1&#x2013;234.e8. 10.1016/j.neurobiolaging.2018.09.010</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2018.09.010</ArticleId><ArticleId IdType="pubmed">30337192</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Mossevelde S, van der Zee J, Gijselinck I, et al. . Clinical evidence of disease anticipation in families segregating a C9orf72 repeat expansion. JAMA Neurol 2017;74:445&#x2013;52. 10.1001/jamaneurol.2016.4847</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2016.4847</ArticleId><ArticleId IdType="pubmed">28192553</ArticleId></ArticleIdList></Reference><Reference><Citation>Xi Z, van Blitterswijk M, Zhang M, et al. . Jump from pre-mutation to pathologic expansion in C9orf72. Am J Hum Genet 2015;96:962&#x2013;70. 10.1016/j.ajhg.2015.04.016</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ajhg.2015.04.016</ArticleId><ArticleId IdType="pmc">PMC4457950</ArticleId><ArticleId IdType="pubmed">26004200</ArticleId></ArticleIdList></Reference><Reference><Citation>Nordin A, Akimoto C, Wuolikainen A, et al. . Sequence variations in C9orf72 downstream of the hexanucleotide repeat region and its effect on repeat-primed PCR interpretation: a large multinational screening study. Amyotroph Lateral Scler Frontotemporal Degener 2017;18:256&#x2013;64. 10.1080/21678421.2016.1262423</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2016.1262423</ArticleId><ArticleId IdType="pubmed">27936955</ArticleId></ArticleIdList></Reference><Reference><Citation>Dolzhenko E, van Vugt JJFA, Shaw RJ, et al. . Detection of long repeat expansions from PCR-free whole-genome sequence data. Genome Res 2017;27:1895&#x2013;903. 10.1101/gr.225672.117</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/gr.225672.117</ArticleId><ArticleId IdType="pmc">PMC5668946</ArticleId><ArticleId IdType="pubmed">28887402</ArticleId></ArticleIdList></Reference><Reference><Citation>Amarasinghe SL, Su S, Dong X, et al. . Opportunities and challenges in long-read sequencing data analysis. Genome Biol 2020;21:30. 10.1186/s13059-020-1935-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13059-020-1935-5</ArticleId><ArticleId IdType="pmc">PMC7006217</ArticleId><ArticleId IdType="pubmed">32033565</ArticleId></ArticleIdList></Reference><Reference><Citation>Jain M, Olsen HE, Paten B, et al. . The Oxford nanopore MinION: delivery of nanopore sequencing to the genomics community. Genome Biol 2016;17:239. 10.1186/s13059-016-1103-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13059-016-1103-0</ArticleId><ArticleId IdType="pmc">PMC5124260</ArticleId><ArticleId IdType="pubmed">27887629</ArticleId></ArticleIdList></Reference><Reference><Citation>Roberts RJ, Carneiro MO, Schatz MC. The advantages of SMRT sequencing. Genome Biol 2013;14:405. 10.1186/gb-2013-14-6-405</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/gb-2013-14-6-405</ArticleId><ArticleId IdType="pmc">PMC3953343</ArticleId><ArticleId IdType="pubmed">23822731</ArticleId></ArticleIdList></Reference><Reference><Citation>Ebbert MTW, Farrugia SL, Sens JP, et al. . Long-read sequencing across the C9orf72 'GGGGCC' repeat expansion: implications for clinical use and genetic discovery efforts in human disease. Mol Neurodegener 2018;13:46. 10.1186/s13024-018-0274-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13024-018-0274-4</ArticleId><ArticleId IdType="pmc">PMC6102925</ArticleId><ArticleId IdType="pubmed">30126445</ArticleId></ArticleIdList></Reference><Reference><Citation>Giesselmann P, Br&#xe4;ndl B, Raimondeau E, et al. . Analysis of short tandem repeat expansions and their methylation state with nanopore sequencing. Nat Biotechnol 2019;37:1478&#x2013;81. 10.1038/s41587-019-0293-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41587-019-0293-x</ArticleId><ArticleId IdType="pubmed">31740840</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>